Thera-SAbDab

AFUTUZUMAB

>   Structural Summary
TherapeuticAfutuzumab
TargetMS4A1
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
Light ChainDIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
100% seqID Fv Structure3pp3 [Fvs: HL, IK], 3pp4 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyGlycoMAb Technology
INN Year Proposed2008
INN Year Recommended2011
Companies InvolvedGLYCART Biotechnology, Biogen Idec, Chugai Pharmaceutical, Dana-Farber Cancer Institute, Genentech, Lymphoma Academic Research Organisation, Nippon Shinyaku, OHSU Knight Cancer Institute, Pharmacyclics, Polish Myeloma Consortium, Roche, Thomas Jefferson University, University of Heidelberg, University of Leeds
Conditions ApprovedChronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin's lymphoma
Conditions ActiveDiffuse large B cell lymphoma, CNS cancer, Graft-versus-host disease, Lupus nephritis, Mantle-cell lymphoma, Waldenstrom's macroglobulinaemia
Conditions DiscontinuedPrimary biliary cirrhosis
NotesObinutuzumab and Afutuzumab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]